FCM检测的CLL-MRD报告方式:CLL-MRD细胞<20个,在报告上写明MRD阴性,或未检测到;如MRD阳性,应根据MRD细胞数占白细胞的百分比报告,同时描述该群细胞的免疫表型特点。例如:<20个CLL细胞,报告:未检测到MRD(LOD:0.01%);在100万个细胞中检测到60个CLL细胞,报告:CLL-MRD=0.006%(LOQ:0.005%);在100万个细胞中检测到...
数据截止至2024年2月6日,24例患者完成了3个周期的OFCG治疗。在3个周期后,通过流式细胞术(Flow Cytometry, FCM)检测,外周血(Peripheral Blood, PB)-uMRD率和BM-uMRD率分别为70.8%和56.6%, ORR和CR/CRi率分别为100%和31.8%。6个...
MRD can be assessed by either based on PCR or on flow cytometry. Both approaches can help detect disease with striking levels of sensitivity. It is now evident that less sensitive and specific techniques (e.g., qualitative PCR and 2-color flow cytometry) are not capable of reaching the ...
developed over the decades»minimal residual disease (MRD) monitoring became an efficient way to assess the treatment effect. Here we reviewed the common methods to test MRD including flow cytometry and molecular detection methods based on PCR technique. Also we introduced the progress of MRD ...
If you have a therapy – for example CAR T-cell therapy – that is known to go deeper in the remission intensity, it makes sense to check serial MRD. Because you want to know, for example, in the blood or in the bone marrow if your therapy is really strong enough to get rid of ...
Aims: Our aim was to determine the capability of immuno-flowFISH using imaging flow cytometry to detect del(17p) and +12 in CLL, and, the lowest limit of detection. We hypothesized that this integrated automated immuno-flowFISH method would be suitable for MRD assessment of CLL. Methods: ...
近年来针对 CLL 的新药层出不穷,微小残留病灶 (minimal residual disease , MRD )监测逐渐 成为评估疗效的重要手段。本文总结了目前常用的 MRD 检测方法,包括流式细胞学和基于 PCR 法的分子学检 测,并介绍了其在初... 文档格式:PDF | 页数:5 | 浏览次数:65 | 上传日期:2019-12-04 15:44:35 | 文档...
流式细胞术(Flow cytometry, FCM)检测白血病细胞的免疫表型(immunophenotyping, IP)是一种能够快速诊断和识别AML复发非常有用的技术,同时复发的现象也反映了目前针对LSC治疗的失败.多参数流式细胞仪通过识别抗原异常的表达模式,在检测白血病微小残留病(minimal residual disease, MRD)上有更大的敏感性,能够早期预测疾病...
Davids cites one of the newest: clonoSeq by Adaptive, which “can provide up to 100-fold more sensitive detection of MRD than the standard flow cytometry tests.” “We’re finding that to be useful to understand depth of response to help counsel patients about their likely durability of ...
“These are very exciting responses across poor prognostic groups, including complete remissions, and although it was not a prospective objective of the trial, where local labs did flow cytometry, they found that some patients were negative for MRD. In the context of a single agent in relapsed/...